AI Cancer Vaccine Achieves 75% Melanoma Response and 3-Year Remission: Evaxion Data at SITC 2026
· techtimes.com · popularity 20/100 · 0 similar stories today · Cancer & Oncology (Health & Life Sciences)
Read the original at techtimes.com →
Summary
Evaxion's AI cancer vaccine EVX-01 achieved 75% response rate in advanced melanoma, with all responding patients remaining in remission at 3 years.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 4.